Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 7/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 6/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 2/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 2/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 2/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 2/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 2/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.71 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.68 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29926966 | 1.00 | APP (1.00) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL1374530 | 0.92 | APP (0.85) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL15307670 | 0.88 | APP (0.79) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL3945554 | 0.87 | AKR1C3 (0.85) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL1371930 | 0.85 | APP (0.82) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL1372754 | 0.83 | AKR1C3 (1.00) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL5448540 | 0.83 | APP (1.00) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL31759329 | 0.82 | APP (0.69) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL2777333 | 0.82 | APP (1.00) | APPCYP2C9CYP2C19AKR1C3AKR1C2 | |
| SCHEMBL1371366 | 0.82 | APP (0.97) | APPCYP2C9CYP2C19AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048031-A1 | POLYMORPHS OF CO-CRYSTALS OF ITANAPRACED AND NICOTINAMIDE | CERESPIR INCORPORATED (US) | 2026-02-19 | — | — | US | claimed |
| WO-2025244939-A1 | POLYMORPHS OF CO-CRYSTALS OF ITANAPRACED AND NICOTINAMIDE | CERESPIR INCORPORATED (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250281638-A1 | Compositions and Methods for Activating Natural Killer Cells | CHIMERA BIOENGINEERING, INC. (US) | 2025-09-11 | — | — | US | claimed |
| EP-4612298-A1 | BCMA VH-ONLY CARS | Dana-Farber Cancer Institute, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4608871-A1 | CD33 ANTIBODY COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE | Memorial Sloan-Kettering Cancer Center (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250213585-A1 | COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR | SHANGHAI INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY (CN) | 2025-07-03 | — | — | US | claimed |
| US-20250161290-A1 | CO-CRYSTALS | CERESPIR INCORPORATED (US) | 2025-05-22 | — | — | US | claimed |
| US-12290515-B2 | Co-crystals | CERESPIR INCORPORATED (US) | 2025-05-06 | — | — | US | claimed |
| WO-2025050066-A1 | COMPOSITIONS INCLUDING SMALL-MOLECULE TERT ACTIVATOR COMPOUNDS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-06 | — | — | WO | claimed |
| US-12226408-B2 | Co-crystals | CERESPIR INCORPORATED (US) | 2025-02-18 | — | — | US | claimed |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | claimed |
| WO-2008006099-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-04 | — | — | US | claimed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | claimed |
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MYRIAD GENETICS, INCORPORATED (US) | 2007-01-18 | — | — | US | claimed |
| WO-2006020850-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020852-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2006020853-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015832-A1 | Methods of treating overactive bladder and urinary incontinence | MME, AVPR1B, AVPR2 | APP 2522/4885CYP2C9 3765/4885CYP2C19 2701/4885 |
| US-20070232672-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 21/4885CYP2C9 1035/4885CYP2C19 540/4885 |
| US-20070232589-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 29/4885CYP2C9 1156/4885CYP2C19 630/4885 |
| US-20250161290-A1 | CO-CRYSTALS | APP, PSEN1, PRNP | APP 1/4885CYP2C9 1310/4885CYP2C19 2175/4885 |
| US-12226408-B2 | Co-crystals | APP, PSEN1, PRNP | APP 1/4885CYP2C9 1310/4885CYP2C19 2175/4885 |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | APP 2/4885CYP2C9 4757/4885CYP2C19 4045/4885 |
| US-12290515-B2 | Co-crystals | APP, PSEN1, PRNP | APP 1/4885CYP2C9 1310/4885CYP2C19 2175/4885 |
| US-20260048031-A1 | POLYMORPHS OF CO-CRYSTALS OF ITANAPRACED AND NICOTINAMIDE | NAMPT, PRNP, NAPRT | APP 8/4885CYP2C9 112/4885CYP2C19 135/4885 |
| US-20070232656-A1 | Pharmaceutical Composition And Method For Treating Neurodegenerative Disorders | ACHE, BCHE, CHAT | APP 21/4885CYP2C9 1035/4885CYP2C19 540/4885 |
| US-20080033045-A1 | TREATMENT OF PSYCHIATRIC DISORDERS | SLC6A3, SLC6A2, FKBP5 | APP 2500/4885CYP2C9 2722/4885CYP2C19 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.